Precision medicine solutions company CareDx Inc (NASDAQ: CDNA), known as The Transplant Company, reported on Tuesday that it presents its latest cardiothoracic advancements at the ISHLT 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic, from 10 to 13 April 2024.
The presentations feature CareDx's cardiothoracic portfolio, including AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung and AiCAV (in development), showcasing real-world applications in over 25 presentations.
Experts discuss the use of CareDx's solutions in clinical decision-making and managing real-world scenarios in two CareDx sponsored symposia, highlighting innovations in heart and lung transplantation care.
Headquartered in Brisbane, California, CareDx is focused on developing high-value healthcare solutions for transplant patients and caregivers, offering testing services, products and digital healthcare solutions.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial